Among the participants of the 20th European Hematology Association (EHA) Congress which took place on 11-14 June in Vienna were also representatives of Celon Pharma S.A.
This year, the Company presented the latest results of research on the development of potential drugs for treatment of leukemias and lymphomas. The data was presented in the form of a poster entitled "Design and development of a novel, highly potent and selective PI3K-delta inhibitor, CPL-302-215, as potential treatment of hematologic malignancies".
During last year's Congress, which was held in Italy, Celon Pharma presented the latest results of research on developing PI3K-delta inhibitors.
The European Hematology Association (EHA) Congress is an event which promotes the idea of improving patient care, research and education on hematology in Europe.